孕激素受体配体治疗子宫内膜异位症:疗效成功与失败背后的机制
本文系统综述了孕激素受体配体治疗子宫内膜异位症的作用机制,指出孕激素通过下调雌激素受体、干扰芳香化酶和17β-羟类固醇脱氢酶1型抑制局部雌二醇生成,并抑制细胞增殖、炎症、新生血管和神经发生。但异位内膜中孕激素受体表达降低且亚型失衡(PRA优势),加之氧化应激和表观遗传异常导致孕激素抵抗,深部内异症对药物缩瘤反应更差。个体遗传特征影响药物生物利用度和药效学,解释部分疗效差异。医疗治疗亟需创新,应从纯激素治疗转向药物组合或新分子以恢复稳态机制。
要点
- 孕激素受体信号下调雌激素受体并抑制局部雌二醇合成,从而抑制异位内膜增殖和炎症。
- 异位内膜孕激素受体表达降低且PRA/PRB失衡,加上氧化应激和表观遗传异常导致孕激素抵抗。
- 深部内异症对药物缩瘤反应更差,个体遗传差异影响激素药物疗效,需转向药物组合或新分子。
核心结论
- 孕激素治疗子宫内膜异位症有时失败,机制涉及孕激素受体表达降低、亚型失衡、氧化应激和表观遗传异常。
- 深部内异症比其他表型更抵抗药物缩瘤,个体遗传特征影响激素药物疗效。
- 医疗治疗需创新,应从纯激素治疗转向药物组合或新分子以恢复稳态机制。
研究设计与样本
- 系统检索PubMed自1958年发表的文章,涉及孕激素、雌孕激素联合和选择性孕激素受体调节剂治疗子宫内膜异位症及其相关症状。
- 两名评审员筛选标题和摘要以选择全文评估文章。
主要发现
- 孕激素受体信号下调雌激素受体,并通过干扰芳香化酶和17β-羟类固醇脱氢酶1型抑制局部雌二醇生成。
- 孕激素抑制子宫内膜异位症中的细胞增殖、炎症、新生血管和神经发生。
- 异位内膜中孕激素受体表达降低且紊乱,PRA亚型优势超过全长活性PRB,由影响PGR基因转录的表观遗传异常所致。
- 氧化应激是子宫内膜异位症孕激素抵抗的另一机制。
- 正常内膜中孕激素的分子靶点(如FOXO1、基质金属蛋白酶、连接蛋白43和雌二醇代谢旁分泌调节因子)在异位内膜细胞中抵抗孕激素作用。
临床怎么用
- 临床应认识到孕激素治疗可能因孕激素抵抗而失败,尤其深部内异症患者缩瘤反应更差。
- 考虑个体遗传特征对激素药物生物利用度和药效学的影响,解释疗效差异。
- 治疗策略需从纯激素治疗转向药物组合或新分子以恢复稳态机制。
局限性
- 本文为综述,未报告原始研究的具体样本量、阈值或统计值。
- 文献检索截至1958年以来发表文章,未明确检索截止日期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite intense research, it remains intriguing why hormonal therapies in general and progestins in particular sometimes fail in endometriosis. OBJECTIVE AND RATIONALE: We review here the action mechanisms of progesterone receptor ligands in endometriosis, identify critical differences between the effects of progestins on normal endometrium and endometriosis and envisage pathways to escape drug resistance and improve the therapeutic response of endometriotic lesions to such treatments. SEARCH METHODS: We performed a systematic Pubmed search covering articles published since 1958 about the use of progestins, estro-progestins and selective progesterone receptor modulators, to treat endometriosis and its related symptoms. Two reviewers screened the titles and abstracts to select articles for full-text assessment. OUTCOMES: Progesterone receptor signalling leads to down-regulation of estrogen receptors and restrains local estradiol production through interference with aromatase and 17 beta-hydroxysteroid dehydrogenase type 1. Progestins inhibit cell proliferation, inflammation, neovascularisation and neurogenesis in endometriosis. However, progesterone receptor expression is reduced and disrupted in endometriotic lesions, with predominance of the less active isoform (PRA) over the full-length, active isoform (PRB), due to epigenetic abnormalities affecting the PGR gene transcription. Oxidative stress is another mechanism involved in progesterone resistance in endometriosis. Among the molecular targets of progesterone in the normal endometrium that resist progestin action in endometriotic cells are the nuclear transcription factor FOXO1, matrix metalloproteinases, the transmembrane gap junction protein connexin 43 and paracrine regulators of estradiol metabolism. Compared to other phenotypes, deep endometriosis appears to be more resistant to size regression upon medical treatments. Individual genetic characteristics can affect the bioavailability and pharmacodynamics of hormonal drugs used to treat endometriosis and, hence, explain part of the variability in the therapeutic response. WIDER IMPLICATIONS: Medical treatment of endometriosis needs urgent innovation, which should start by deeper understanding of the disease core features and diverse phenotypes and idiosyncrasies, while moving from pure hormonal treatments to drug combinations or novel molecules capable of restoring the various homeostatic mechanisms disrupted by endometriotic lesions.
引用
- Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020. PMID: 32412587. doi:10.1093/humupd/dmaa009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。